Introduction {#s1}
============

Central airway obstruction (CAO) is an uncommon but potentially life-threatening condition that can be due to a number of malignant diseases. For example, airway obstruction complicates approximately 20-30% of patients with lung cancer \[[@R01]\]. This can result from either the direct endobronchial extension of a tumor or extrinsic compression from parenchymal lung mass, lymph-node, and esophageal or thyroid cancer \[[@R02]\]. Clinically, malignant CAO presents with dyspnea, stridor, or cough. Radiologically, it can present with lobar or complete lung atelectasis. Physiologically, it can manifest as air flow obstruction on spirometry with characteristic changes in flow volume loop (FVL) such as blunting of the expiratory and inspiratory limb of the FVL in case of fixed airway obstruction, or biphasic FVL in case of unilateral mainstem bronchus obstruction \[[@R02], [@R03]\]. Interventional bronchoscopy with airway stenting by virtue of re-establishment of the patency of the airway provides immediate relief of dyspnea, resolution of radiological and physiological changes, improves functional status, and confers stabilization of clinical condition to allow administration of definitive therapies targeted at cancer \[[@R02]\]. Other interventional bronchoscopic techniques used for the recanalization of the malignant CAO are the laser resection, coring of the tumor with the rigid tube, and brachytherapy \[[@R02]\]. In addition to palliation, survival benefit has also been described if performed early \[[@R04]\]. In CAO from extrinsic compression, two types of stents are used for recanalization. Silicone stents are preferred for benign diseases, whereas metal stents can be used for malignant CAO \[[@R05]\]. We describe our clinical experience in using self-expanding metal stent (SEMS) for malignant CAO.

Materials and Methods {#s2}
=====================

We performed a retrospective analysis of 16 patients treated with SEMS for malignant CAO from January 1, 2014 to November 30, 2015. We collected data on oxygenation, radiographic changes, bronchoscopic appearance, type of intervention, complications of intervention, safety, and effectiveness of SEMS. Approval from our institutional review board was obtained.

Flexible and rigid bronchoscopies were performed using standard techniques \[[@R01]\]. Nd-YAG laser resection (Laser sonic Model 8000; Heraeus Surgical, Milpitas, CA) was performed using 15- to 30-W pulses and pulse duration of 0.5 - 1.0 s. Coring of the tumor was carried out using the rigid tube where necessary. Flexible bronchoscopy through the rigid tube was employed as necessary to help clear the airways of secretions and blood. In cases with extrinsic compression from malignant obstruction, Boston Scientific Ultraflex SEMSs were deployed using the Ultraflex^TM^ Tracheobronchial Stent System via standard technique. Only covered Ultraflex self-expanding stents were used. Covered SEMSs are coated with a silicone sheath except 0.5 cm of their proximal and distal end.

Definitions {#s2a}
-----------

CAO was defined as the obstruction of the trachea and mainstem bronchi. Respiratory failure was defined as stridor, need for supplemental oxygen, or need for mechanical ventilation. Survival was calculated from date of diagnosis-to-date of death or November 30, 2015.

Data analysis {#s2b}
-------------

We used software (SPSS, version 17; SPSS, Chicago, IL) for all statistical analyses. The results were compared using a Wilcoxon two-sample test or Fisher's exact test. P values were two-sided and considered indicative of a significant difference if less than 0.05.

Results {#s3}
=======

Sixteen patients (11 males and five females) underwent stenting in 1 year. Median (range) age was 66 (54 - 78) years. Eighteen stents were placed in 16 patients, with one patient needing two stents in both bronchi and one needing two adjacent stents in right main bronchus and bronchus intermedius ([Fig. 1](#F1){ref-type="fig"}). Nine (56.2%) patients had primary lung cancer, five (31.2%) had esophageal cancer, and two (12.5%) had thyroid cancer. Three patients received mechanical ventilation before the procedure ([Table 1](#T1){ref-type="table"}). Two patients underwent concurrent laser prior to stent placement. Four patients had lobar or complete lung atelectasis on presentation. Procedures were done under general anesthesia in operation room via the rigid bronchoscopy. No perioperative or immediate postoperative complications were seen except acute myocardial infarction (AMI) on day after the procedure in one patient. Three patients were transferred to intensive care unit (ICU) for closer monitoring after the procedure and were discharged the next day. All four patients with lung atelectasis on presentation experienced complete re-expansion of the lung post-stenting. The dyspnea was substantially relieved in 14 patients (87.5%). All three patients who were intubated prior to intervention were weaned off from the ventilator following stent insertion.

![Representative case of malignant central airway obstruction in a 60-year-old male with squamous cell carcinoma. (A) Complete right lung collapse on the radiograph at the time of initial presentation with the cut off of the right main bronchus (arrow). (B) CT scan of the chest (axial view) showing collapsed right lung. (C) Visible endobronchial tumor obstructing the right main bronchus on bronchoscopy. (D) Re-expansion of the right lung following the SEMS placement in the right main bronchus and bronchus intermedius (arrow). (E) Post-stent placement CT scan of the chest (axial view) showing re-expansion of the right lung and stent in-situ (arrow). (F) CT scan of the chest 1 year later showing tumor ingrowth and recurrence of lung collapse.](jocmr-09-058-g001){#F1}

###### General Characteristics of Patients (n = 16)

  SN/age/gender               Type of cancer                 Airway lesions                                                        Radiology findings                                                     Site of stent    Stent dimensions         Other therapy
  --------------------------- ------------------------------ --------------------------------------------------------------------- ---------------------------------------------------------------------- ---------------- ------------------------ ---------------------------------------------------------------
  Lung cancer (n = 9)                                                                                                                                                                                                                               
  1/78/F                      Non-small cell carcinoma       Mid-trachea stenosis                                                  4.4 × 3.5 cm mass in superior mediastinum compressing the trachea      Mid-trachea      16 × 40 mm               Nil
  2/63/M                      Sarcomatoid cancer             RMB obstruction                                                       RUL mass                                                               RMB              12 × 40 mm               RT
  3/61/M                      Squamous cell carcinoma lung   RMB and BI obstruction                                                4.5 × 4.7 × 4.6 cm Rt. hilar mass with complete collapse if Rt. lung   RMB and BI       14 × 40 and 14 × 40 mm   RT and chemotherapy
  4/58/M                      Adenocarcinoma lung            RMB obstruction                                                       12.8 × 7.7 × 7.5 cm RUL mass with SVC obstruction                      RMB              16 × 40 mm               Nil
  5/74/F                      Adenocarcinoma lung            RMB obstruction                                                       RUL mass with collapse of RUL                                          RMB              12 × 40 mm               RT (9\#)
  6/70/M                      Squamous cell carcinoma        Mid-tracheal and RMB obstruction                                      \-                                                                     Trachea          16 × 40 mm               Chemotherapy and RT
  7/70/M                      Squamous cell carcinoma        Distal trachea, proximal Rt. Main and proximal Lt. main obstruction   Infiltrate                                                             Right and LMB    12 × 40 and 12 × 40 mm   RT (35\#)
  8/77/M                      Squamous cell carcinoma                                                                              \-                                                                     RMB              10 × 40 mm               RT
  9/67/F                      Squamous cell carcinoma        Distal trachea narrowing to 0.4 cm and Rt. Main obstruction           6.1 × 5.5 × 6.5 cm RUL mass with tracheal compression                  Distal trachea   16 × 40 mm               RT (12\#)
  Esophageal cancer (n = 5)                                                                                                                                                                                                                         
  10/58/M                     Squamous cell carcinoma        LMB obstruction                                                       5.2 × 3.8 × 2.4 cm mass in posterior mediastinum                       LMB              14 × 40 mm               Ivor-lewis surgery with chemotherapy and RT prior to stenting
  11/66/M                     Squamous cell carcinoma        LMB obstruction                                                       \-                                                                     LMB              14 × 40 mm               
  12/68/M                     Squamous cell carcinoma        LMB obstruction                                                       \-                                                                     LMB              14 × 40 mm               Chemotherapy and RT
  13/55/M                     Squamous cell carcinoma        LMB obstruction                                                       \-                                                                     LMB                                       Chemotherapy
  14/63/M                     Adenocarcinoma                 LMB esophageal fistula                                                Bilateral infiltrates from aspiration pneumonia                        LMB              18 × 40 mm               Ivor-lewis surgery prior to stenting
  Thyroid cancer (n = 2)                                                                                                                                                                                                                            
  15/54/F                     Anaplastic thyroid carcinoma   Upper tracheal narrowing to 0.5 cm                                    5.2 × 6.2 × 6.4 cm mass in the thyroid gland                           Upper trachea                             Nil
  16/76/F                     Anaplastic thyroid carcinoma   Sub-glottis and upper tracheal stenosis                               6.6 × 3.3 × 5.6 cm mass in the thyroid gland                           Upper trachea    18 × 60 mm               Nil

RUL: right upper lobe; Rt.: right; LMB: left main bronchus; RMB: right main bronchus; BI: bronchus intermedius; RT: radiotherapy; \#: number of fractions of radiotherapy.

During follow-up, granulation tissue (n = 1), mucostasis (n = 1), and tumor ingrowth (n = 2) were the most frequently encountered complications. Median survival from the date of diagnosis and the date of stent placement in from lung cancer, esophageal cancer, and thyroid cancer were 140 (21 - 564) and 85 (15 - 361), 288 (80 - 419) and 61 (60 - 171), and 129 (71 - 187) and 67 (16 - 118) days, respectively. This survival was similar to expected survival based on the life expectancy of the underlying malignancy ([Table 2](#T2){ref-type="table"}) \[[@R06]\].

###### Survival of Patients Having Malignant COA and Treated With SEMS in Comparison to the Expected Survival Associated With the Underlying Malignancy (n = 16)

                                                      Respiratory failure   Diagnosis-to-stenting time (days)   Diagnosis-to-death time or last follow-up time (actual life expectancy in days)   Stenting-to-death or last follow-up (days)   Expected life expectancy
  --------------------------------------------------- --------------------- ----------------------------------- --------------------------------------------------------------------------------- -------------------------------------------- ---------------------------------
  Non-small cell lung cancer                          Yes                   14                                  74                                                                                60                                           
  Sarcomatoid cancer                                  Yes                   40                                  220                                                                               180                                          
  Squamous cell carcinoma lung                        Yes                   1                                   362                                                                               361                                          
  Adenocarcinoma lung                                 Yes                   39                                  54                                                                                15                                           
  Adenocarcinoma lung                                 No\*                  11                                  347                                                                               336                                          
  Squamous cell carcinoma                             No                    516                                 564                                                                               48 (alive)                                   
  Squamous cell carcinoma                             Yes                   -12                                 140                                                                               152 (alive)                                  
  Squamous cell carcinoma                             No                    4                                   89                                                                                85 (alive)                                   
  Squamous cell carcinoma                             Yes                   6                                   21                                                                                15 (alive)                                   
  Lung cancer (n = 9), median (range)                                       11 (-12 - 516)                      140 (21 - 564)                                                                    85 (15 - 361)                                10 (8 - 12) months \[[@R13]\]
    Squamous cell carcinoma                           Yes                   323                                 419                                                                               96                                           
    Squamous cell carcinoma                           No                    299                                 360                                                                               61                                           
    Squamous cell carcinoma                           Yes                   117                                 288                                                                               171                                          
    Squamous cell carcinoma                           No                    20                                  8                                                                                 60                                           
    Adenocarcinoma                                    Yes                   56                                  117                                                                               61                                           
  Esophageal cancer (n = 5), median (range)                                 117 (20 - 323)                      288 (80 - 419)                                                                    61 (60 - 171)                                9 (8 - 10) months \[[@R15]\]
    Anaplastic thyroid carcinoma                      Yes                   55                                  71                                                                                16                                           
    Anaplastic thyroid carcinoma                      Yes                   69                                  187                                                                               118                                          
  Anaplastic thyroid cancer (n = 2), median (range)                         62 (55 - 69)                        129 (71 - 187)                                                                    67 (16 - 118)                                3.8 (3 - 4.6) months \[[@R14]\]
  All (n = 16)                                                              39.5 (-12-516)                      163.5 (21 - 564)                                                                  73 (15 - 361)                                

\*Patients without respiratory failure in the lung carcinoma group underwent stent placement to prevent worsening of the airway obstruction secondary to radiation therapy. Patients without respiratory failure in the esophageal carcinoma group underwent stent placement prior to esophageal stenting to prevent airway compromise from esophageal stenting.

Discussion {#s4}
==========

This study illustrates that SEMSs are safe and effective for managing malignant CAO. They provide prompt reversal of respiratory failure and re-expansion of the collapsed lung. By reversing respiratory failure, they avert premature death and allow cancer targeted therapy to be undertaken. This restores the length of survival to the expected life expectancy associated with the primary cancer.

CAO develops secondary to endoluminal disease, external compression by a mediastinal or hilar tumor, bulky lymphadenopathy, or a combination of endoluminal and extrinsic disease \[[@R11]\]. There are a variety of treatment options that can restore airway patency in this group of patients \[[@R12]\]. Stents are employed when extrinsic compression is the dominating cause of the CAO. However, generally, airway stenting is combined with some form of endoscopic tumor resection to achieve patency of the airway.

It is known that survival of patients with untreated malignant CAO is very poor and ranges from 1 to 2 months \[[@R16], [@R17]\]. Life expectancy in untreated advanced lung cancer is 4 - 5 months \[[@R06]\]. Platinum-based chemotherapy improves survival in this group to 8 - 12 months \[[@R06]\]. Similarly life expectancies in advanced esophageal carcinoma and anaplastic thyroid carcinoma are 9 (8 - 10) and 3.8 (3 - 4.6) months, respectively \[[@R07]\]. In this context, despite having CAO, patients in our cohort lived to the level of the expected life expectancy associated with the underlying malignancy. The described and perceived benefits of the stenting are mainly relief of dyspnea, improved functional status, and better quality of life \[[@R18]\]. However, it is noteworthy that even though stenting does not increase survival *per se*, it supports survival by preventing premature death from respiratory failure, post-obstructive pneumonitis, and sepsis. It is also shown that patients having advanced lung cancer with locally treated malignant CAO in combination with chemotherapy live as long as their counterparts without CAO \[[@R18]\].

The American College of Chest Physicians (ACCP) has published an advisory against using metal stents in benign airway obstruction. Silicone stents are preferable in such diseases due to their ease of removal and re-introduction \[[@R05]\]. Some centers prefer silicone stents even for malignant CAO. However, limited life expectancy of patients with malignant CAO obviates the need for removal of the stent upon resolution of the stenosis. We found SEMS effective in restoring and maintaining the airway patency and at the same time easy to introduce and safe with no peri-procedural complications or mortality. Relative ease of their insertion carries the potential to broaden the proportion of patients they can be offered to.

We found that lung cancer patient with CAO presents at the time of initial diagnosis, whereas patients with thyroid carcinoma and esophageal carcinoma develop CAO significantly later in the course of their disease. In our cohort, CAO developed at the median interval of 3.9 months after the diagnosis of esophageal cancer, and 2 months after the diagnosis of thyroid cancer. Since early intervention is preferable, this information can allow physicians to determine the timing of follow-up in outpatient clinic and time for repeating the imaging study to look for the development of CAO with the intent to identify and intervene early before the development of significant airway compromise.

Regarding complications of the SEMS, mucostasis, granulation tissue formation, and tumor ingrowth at the edges of the stent were seen, out of which tumor ingrowth was the most frequent and detrimental complication as it compromised the patency of the airway irreversibly. No patient experienced stent migration (the most significant and frequent complication of the silicone stents) in our cohort even after the resolution of CAO from radiotherapy and chemotherapy. Complications associated with SEMSs are well documented. In a retrospective analysis of 68 patients undergoing Ultraflex SEMSs insertion for malignant tracheobronchial stenosis, most of which were uncovered, complications included hemorrhage originating in the area of the stent placement during the insertion itself (one patient), mild hemoptysis (five patients), stent migration (four patients), severe granulation tissue (three patients), pneumonia (two patients), odynophagia, respiratory failure, stent occlusion, and deployment failure (one patient in each case). There were no episodes of fistula formation, lobe collapse, pneumothorax or sudden death \[[@R19]\]. In another study of 82 patients, Saad et al reported the occurrence of infection in 15.9%, obstructive granulomas in 14.6%, and migration in 4.7% \[[@R20]\]. Most of the patients received an uncovered stent in this cohort too. In a study by Breitenbucher et al in patients with malignant diseases, they observed a complication of mucus plugging in 8% of the cases, as well as stent migration, the formation of granulation tissue and the re-stenosis of the tumor in 5% of cases, each \[[@R21]\]. The lower incidence of stent migration in our cohort is consistent with the existing literature ([Table 3](#T3){ref-type="table"}) \[[@R02], [@R19]\]. In comparison with silicone stents, Ultraflex stents have a lower rate of migration due to their epithelialization, but with a higher rate of granulation tissue formation \[[@R21]\]. Stents were patent in most patients until the time of death as evidenced by computed tomography (CT) or bronchoscopy done close to the time of death indicating that prognosis of underlying cancer was the determinant of length of survival rather than stent failure.

###### Complications of Stent Placement in Malignant Central Airway Obstruction

                       McGrath et al \[[@R19]\] (n = 68)   Saad et al \[[@R20]\] (n = 82)   Cavaliere et al \[[@R02]\] (n = 306)   Breitenbucher et al \[[@R21]\] (n = 60)   Current study (n = 16)
  -------------------- ----------------------------------- -------------------------------- -------------------------------------- ----------------------------------------- ------------------------
  Type of stent        Ultraflex SEMS                      Ultraflex SEMS                   Silicone stents                        Ultraflex SEMS                            Covered Ultraflex SEMS
  Covered/uncovered    Uncovered (94%)                     Uncovered (66%)                  Not applicable                         Uncovered (18.3%)                         Uncovered (0)
  Migration            4(5.8%)                             4.7%                             18 (6%)                                5%                                        0
  Granulation tissue   3 (4.4%)                            14.6%                            3 (0.9%)                               5%                                        1 (6.2%)
  Mucostasis           Not reported                        Not reported                     3 (0.9%)                               8%                                        1 (6.2%)
  Tumor ingrowth       1 (1.4%)                            Not reported                     Not reported                           5%                                        2 (12.5%)
  Pneumonia            2 (2.9%)                            15.9%                            5 (1.6%)                               10%                                       0

In conclusion, SEMSs not only offer minimally invasive palliative therapy for patients suffocating from un-resectable malignant CAO with low complication risk, but also preserve survival by averting premature death from respiratory failure, and conferring clinical stability to allow cancer targeted therapy to take place. Tumor ingrowth at the uncovered edges of the stent is the most significant and irreversible complication. Completely covered SEMSs may help to overcome this complication.
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